An Agora for the Medical Student Community | 17 | Creating Innovative
As first-year medical students at Albany Medical College, authors Aleena Paul and Ajay Major founded in-Training, an online peer-reviewed publication by and for
Related Articles
Hematopoiesis
Hematopoiesis is a quarterly collection of articles written by and for trainees, and curated by the ASH Trainee Council.
October
Provided to YouTube by NAXOS of AmericaOctober · North Texas Wind SymphonyNorth Texas Wind Symphony: Passions℗ 2005 KlavierReleased on: 2005-01-01Composer: E…
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors…
Mixed-Methods Study of End-of-Life Experiences of Patients With Hematologic Malignancies in Social Hospice Residential Home Care Settings
PURPOSE Hospice is underutilized by patients with hematologic malignancies (HM), and when patients are referred, they are typically more ill, hospitalized, and with shorter length…
“What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients | NEJM
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
“What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients | NEJM
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
“What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients | NEJM
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
BISON-PRO Quality of Life Study
A prospective repository of longitudinal, real-world patient-reported outcomes (PRO) and quality of life data for patients with blood disorders.
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas
Abstract. Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen re
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas
Abstract. Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen re